About: Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 1997

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 1997 (uk) articolo scientifico (pubblicato il 1997) (it) im Januar 1997 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xineru de 1997 (ast) artikull shkencor i botuar më 01 janar 1997 (sq) scientific article published on 01 January 1997 (en)
publication date	wds:Q71958863-2D2BE0A4-7E23-4AE7-9903-1359A3984742
publication date	1997-01-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71958863-142E840F-EC99-4242-ABB2-CBBF8470147B
language of work or name	English
rdfs:label	Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group (en) Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group (nl) Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group (sq)
skos:prefLabel	Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group (en) Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group (nl) Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group (sq)
name	Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group (en) Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group (nl) Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group (sq)
title	wds:Q71958863-E8857FDE-2AE2-481B-97BF-0067EE8693B3
title	Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group (en)
page(s)	wds:Q71958863-CE881A0C-02F0-4271-9B12-1242303C1C41
page(s)	93-99
instance of	wds:Q71958863-384D0965-80BD-4194-8FF1-595E6BA0B257
instance of	scholarly article
main subject	wds:Q71958863-9076B6A1-6D80-4829-B493-09EF115ABC0B wds:Q71958863-BB6148D2-196B-4A23-A5BC-E5D0D4863989
main subject	bronchopulmonary dysplasia virus
PubMed ID	wds:Q71958863-B636FB36-3FDE-48E8-B08D-9D2C3D9B436E
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8989345
PubMed ID	8989345
published in	wds:Q71958863-3AFDE78F-E9E7-45DE-93B5-0BB5C2A41ADC
published in	Pediatrics
issue	wds:Q71958863-39655116-D879-4057-8F6F-361B69C9843D
volume	wds:Q71958863-8BE53BB5-B14D-4B11-B190-2546B35FB776
issue	1
volume	99
DOI	wds:Q71958863-633075A4-93D2-4D57-9453-F255F0F55D8C
DOI	http://dx.doi.org/10.1542/PEDS.99.1.93
DOI	10.1542/PEDS.99.1.93
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71958863
is cites work of	Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group Immunoglobulin for preventing respiratory syncytial virus infection Cost effectiveness of palivizumab in Spain: an analysis using observational data. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations Substantial variability in community respiratory syncytial virus season timing Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings Maternal vaccines Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats Respiratory Syncytial Virus: Update on Infection, Treatment, and Prevention Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection Statement on the care of the child with chronic lung disease of infancy and childhood Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years Neonatal oxygen increases sensitivity to influenza A virus infection in adult mice by suppressing epithelial expression of Ear1 Intranasal antibody prophylaxis for protection against viral disease. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice Management of infections caused by respiratory syncytial virus Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease Respiratory syncytial virus infection: therapy and prevention Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery Treatment of respiratory virus infections Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses Advances in prevention of respiratory syncytial virus infections Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection Respiratory syncytial virus infection Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia Animal pneumoviruses: molecular genetics and pathogenesis The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection in calves Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin Palivizumab for respiratory syncytial virus prophylaxis Passive immunity in prevention and treatment of infectious diseases Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review [Prospective regional study of an epidemic of respiratory syncytial virus (RSV) bronchiolitis] Roadblocks to translational challenges on viral pathogenesis Respiratory syncytial virus (RSV) disease and prospects for its control PROPHYLACTIC ANTIBODY TREATMENT AND INTRAMUSCULAR IMMUNIZATION REDUCE INFECTIOUS HUMAN RHINOVIRUS 16 LOAD IN THE LOWER RESPIRATORY TRACT OF CHALLENGED COTTON RATS. Parainfluenza viruses A risk-benefit assessment of drugs used for neonatal chronic lung disease Bronchopulmonary dysplasia in the 1990s: a review for the pediatrician Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines Respiratory syncytial virus genetic and antigenic diversity New insights for development of a safe and protective RSV vaccine Influence of common non-synonymous Toll-like receptor 4 polymorphisms on bronchopulmonary dysplasia and prematurity in human infants

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software